Protalix
NYSE PLX · Hackensack, NJ
Works in Cardiovascular · Genetic & rare · Metabolic & endocrine · Musculoskeletal · Neurology · Renal & urogenital · Women's health
Protalix is a clinical trial sponsor based in Hackensack, NJ, listed as NYSE PLX. It has 1 active clinical trial with 150 planned participants, across 7 therapeutic areas. Since 2021 it has completed 6 trials and stopped 0 early.
Trial track record · since 2021
Financials · NYSE PLX
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
Questions about Protalix
Protalix is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 150 planned participants, in Cardiovascular, Genetic & rare, Metabolic & endocrine, Musculoskeletal and other areas. Since 2021 it has completed 6 trials and stopped 0 early.
Protalix is based in Hackensack, NJ and is listed as NYSE PLX. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Protalix; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-29.
Approve Suite is not affiliated with Protalix.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.